Physician profile
Manisha Patel
NPI 1801972500
$3,007.40
in general payments reported to CMS, 2019-2025
29 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $317 · 2021: $425 · 2022: $739 · 2023: $469 · 2024: $243 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $366.48 | 2021-2025 | |
| Abbvie INC. | $329.61 | 2019-2023 | |
| Therapeuticsmd, INC. | $276.53 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $264.89 | 2019-2023 | |
| Exeltis, USA INC. | $255.19 | 2019-2023 | Slynd |
| Astellas Pharma US INC | $156.31 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $123.98 | 2019-2022 | |
| Olympus America INC. | $112.77 | 2019 | |
| Renovia INC | $112.74 | 2021 | |
| Coopersurgical, INC. | $102.63 | 2019-2023 | Paragard T 380a |
| Janssen Biotech, INC. | $99.00 | 2019 | |
| Evofem Biosciences, INC. | $93.98 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $84.69 | 2023-2024 | Myfembree |
| Exact Sciences Corporation | $84.51 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Aspira Women'S Health INC | $79.97 | 2022-2023 | Ova1 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $69.10 | 2019-2024 | Intrarosa, Femring |
| Amag Pharmaceuticals, INC. | $57.68 | 2019-2020 | |
| Hologic Sales and Service, LLC | $54.66 | 2020-2021 | |
| Shield Therapeutics INC | $48.91 | 2023-2024 | Accrufer |
| Vertical Pharmaceuticals, LLC | $39.10 | 2019 | |
| Myovant Sciences INC. | $35.69 | 2022 | |
| Allergan, INC. | $23.70 | 2019 | |
| Daiichi Sankyo INC. | $23.46 | 2021 | |
| Emd Serono, INC. | $22.33 | 2019 | |
| Bausch Health US, LLC | $21.97 | 2025 | Aplenzin |
| Mylan Pharmaceuticals INC. | $19.98 | 2020 | |
| Roche Diagnostics Corporation | $18.63 | 2019 | |
| Avion Pharmaceuticals | $14.92 | 2019 | |
| Agile Therapeutics, INC. | $13.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.